Raymond James Boosts ICU Medical (NASDAQ:ICUI) Price Target to $158.00

ICU Medical (NASDAQ:ICUI) had its target price raised by Raymond James from $135.00 to $158.00 in a research report released on Thursday morning, Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

Separately, Needham & Company LLC reaffirmed a hold rating on shares of ICU Medical in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $138.33.

ICU Medical Trading Up 0.9 %

Shares of ICUI stock traded up $1.36 on Thursday, reaching $152.71. The company had a trading volume of 567,547 shares, compared to its average volume of 281,822. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. The stock has a market cap of $3.72 billion, a PE ratio of -62.33 and a beta of 0.69. The company has a 50-day moving average of $121.24 and a 200-day moving average of $108.10. ICU Medical has a 12 month low of $78.28 and a 12 month high of $153.55.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. ICU Medical’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 EPS. On average, equities analysts forecast that ICU Medical will post 3.5 earnings per share for the current year.

Insider Activity at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 12,539 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $103.95, for a total transaction of $1,303,429.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Elisha W. Finney sold 300 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $104.95, for a total value of $31,485.00. Following the completion of the sale, the director now owns 2,129 shares of the company’s stock, valued at approximately $223,438.55. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Christian B. Voigtlander sold 12,539 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $103.95, for a total value of $1,303,429.05. The disclosure for this sale can be found here. In the last three months, insiders sold 14,889 shares of company stock worth $1,630,340. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of ICU Medical by 14.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock valued at $19,227,000 after buying an additional 23,816 shares during the last quarter. WCM Investment Management LLC raised its stake in ICU Medical by 37.5% in the 4th quarter. WCM Investment Management LLC now owns 242,808 shares of the medical instruments supplier’s stock valued at $24,223,000 after acquiring an additional 66,221 shares during the period. Principal Financial Group Inc. raised its stake in ICU Medical by 37.8% in the 4th quarter. Principal Financial Group Inc. now owns 107,335 shares of the medical instruments supplier’s stock valued at $10,706,000 after acquiring an additional 29,464 shares during the period. Scout Investments Inc. raised its stake in ICU Medical by 16.3% in the 1st quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after acquiring an additional 7,272 shares during the period. Finally, Maryland State Retirement & Pension System bought a new stake in ICU Medical in the 4th quarter valued at $890,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.